A series of reports on the 2016 annual report of the listed pharmaceutical companies and the first quarter of 2017 were welcomed by the medical network on May 31. Coincided with the Dragon Boat Festival holiday is coming, small make up a summary released before the listed drug firms report analysis report, let everybody in the overall situation of comprehensive review of various performance dragon-boat festival holiday.
2016 annual report disclosure of drama, 183 a-share listed companies (classified by tongda letter pharmaceutical manufacturing sector) also be clear at A glance out A whole year, many companies net profit of other companies is to "kill". Below, the new kang group analyses the three major sectors of chemical, Chinese and biopharmaceutical, looking at where the most high-net profits are.
Chemical company net profit TOP3
Fosun pharmaceuticals: net profit was 28.06 billion yuan, up 14.05% year on year
In 2016, fosun's operating income was 14.629 billion yuan, up 16.02 percent from the same period a year earlier. The net profit of the listed company's shareholders was 28.06 billion yuan, up 14.05 percent year on year.
Core products have grown steadily. In terms of sub-division, fosun's pharmaceutical manufacturing and research and development operations reached 10.26 billion yuan, up 14.83 percent from 2015, accounting for 70.27 percent of revenue. The medical service business reached 16.78 billion yuan, up 21.67 percent from 2015. Product, its resistance to infection disease, metabolic, and digestive system diseases, diseases of the cardiovascular system in the field of core product to occupy a major source of revenue. In 2016, according to its annual report, fosun medicine with a total of 18 preparation item or series of sales over one hundred million yuan, oda gold, optimal emperor, cefmetazole, o extension moran etc series products or sales are more than 500 million yuan.
Annual report showed that during the reporting period, fosun pharma group business growth, sales structure to optimize, marketing system and supply chain integration effect, consortium sinopharm continue to maintain rapid growth.
Hengrui medicine: net profit 25.89 billion yuan, up 19.22% year on year
In 2016, hengrui pharmaceuticals realized operating income of 110.94 billion yuan, up 19.08 percent from the same period a year ago. The net profit of the listed company's shareholders was 25.89 billion yuan, up 19.22 percent year on year.
R&d investment continued to grow. In 2016, its r&d expenditure reached 11.84 billion yuan, up 32.82 percent from a year earlier, accounting for 10.68 percent of revenue, according to the company's annual report. As you can see from the annual report, the r&d investment of hengrui is one of the highest in the industry. Is at the same time, the growth of the r&d hengrui pharmaceutical performance of steady growth, and growth point is no longer just limited to the antitumor drugs: antitumor drug income is 4.83 billion yuan in 2016, up 25.68% from a year earlier. The revenue of the contrast agent was 1.31 billion yuan, up 30.05% year-on-year. Sales of surgical anesthesia products were 3.01 billion yuan, up 19.14 percent year on year.
In addition, hengrui pharmaceutical investment activities generated cash flow net is an increase of 2.179 billion yuan of the previous period, mainly for the construction of fixed assets during the reporting period and pay cash increase to buy bank financing products.
Andy Sue: net profit of 18.65 billion yuan, up 22.03 percent year on year
In 2016, Andy su's operating income was 10.688 billion yuan, down 29.56 percent from a year earlier. The net profit of the listed company's shareholders was 18.65 billion yuan, up 22.03 percent year on year.
The main products are performing well. In 2106, Andy su was the second largest market in the world, with 27% of the market. Sales of each product line have been boosted by increasing global demand, and by removing bottlenecks in existing devices. And the gains are driven by factors such as exchange rates and higher prices for oil derivatives.
The attached:
The 75 a-share chemical pharmaceutical companies have reported earnings and net profit for 2016
Note: listed companies are classified according to the general letter; The data is based on the eastern wealth network, which is ranked according to the net profit margin.
The net profit of Chinese drug companies was TOP3
Conus pharmaceuticals: net profit 33.4 billion yuan, up 21.17% year on year
In 2016, the company's operating income was 216.42 billion yuan, up 19.79% from the same period a year earlier. Net income of the listed company's shareholders was 3.34 billion yuan, up 21.7 percent year on year.
The drink has a solid status. In terms of product: 4.7 billion yuan in traditional Chinese medicine and Chinese medicine, up 26.4% year on year. The trade in Chinese medicine was 57.9 billion yuan, down by 4.0% year on year. Drug circulation was 10 billion yuan, up 34 percent year on year. Medical equipment was 1.32 billion yuan, up 45% year on year. Health food was 17.4 billion yuan, up 23.2 percent year on year. Reason according to its annual report, that growth is largely due to its advantage of traditional Chinese medicine yinpian position has solid - 2016 sig pharmaceutical pharmaceutical income 4.704 billion yuan, Chinese medicine yinpian products increased 26.43% year on year. At the same time, the benefits of the "two-ticket" and other circulation policies affected the pharmaceutical trade pharmaceutical industry in 2016, which was 7301 million yuan, up 35.35 percent year on year.
Yunnan baiyao: net profit of 2.92 billion yuan, up 5.38 percent year on year
In 2016, the revenue of yunnan baiyao was 22411 million yuan, up 8.06 percent year on year. Net profit was 2.92 billion yuan, up 5.38 percent year on year.
Great health arrangements stand out. Now yunnan baiyao by expanding market segment in the big health area, built with drugs (central, and generic drug through skin), cosmetic products, health products, medicine, business, the four traditional Chinese medicine resources business sectors, products a total of more than 390 varieties of 19 dosage forms. With hemostatic analgesia, detumescence huayu, among them as the main efficacy of products including yunnan baiyao band-aid, yunnan baiyao aerosol, yunnan white ointment and so on, more than three products continue to occupy the Chinese market sales of similar products first. Oral care, such as yunnan baiyao toothpaste, accounted for 16.49% of the total toothpaste market in China, ranking second in the same category. Echelon results showing its great health product, such as the qi and blood, raising yuan qi kang products green wash hair care series products and in the ravine of the mask series products, represented by lyophilization and super fine powder technology panther 737, etc.
Dongarakan: net profit of 18.52 billion yuan, up 14% year on year
In 2016, the company made a revenue of 6.317 billion yuan, a year-on-year increase of 15.92 percent. Net profit for listed companies was 18.5.2 billion yuan, up 14 percent from a year earlier.
The gelatin series is a major source of revenue. In the sector, pharmaceutical industry accounted for the largest share of revenue, with 65.21 billion yuan in pharmaceutical industry revenue in 2016, accounting for 88.98 percent of operating income. Pharmaceutical businesses received 266 million yuan in revenue in 2016, accounting for 4.21 percent of revenue. In terms of product, the product of the series of products is 53.71 billion yuan in revenue in 2016, with a gross margin of 74.11 percent, which is among the highest in Chinese pharmaceutical enterprises. The company raised gelatin piece respectively at the end of 2016, glue mucilage and peach blossom kyi glue paste the ex-factory price of 14%, 14%, 28%, from the fourth quarter sales data, the price has not been significant decline. Dongaral's revenue was 23.3.2 billion yuan in the fourth quarter, net profit of 627 million yuan, up by 40.10 percent and 26.52 percent respectively.
The attached:
The results of 2016 and net profit of 71 a-share companies
Note: listed companies are classified according to the general letter; The data is based on the eastern wealth network, which is ranked according to the net profit margin.
Biopharmaceutical company net profit TOP3
Leshi, Shanghai: net income was 16.13 billion yuan, up 11.84 percent year on year
In 2016, the company realized revenue of 23.26 billion yuan, up 15.54% year on year. The net profit of the listed company's shareholders was 16.13 billion yuan, up 11.84 percent year on year. The net profit margin was 69.34%.
Plasma station layout and plasma utilization are dominant. According to the annual report of the Shanghai laishi, there are 35 single plasma stations (including two under construction), with a capacity of nearly 900 tons per year. Shanghai alex is the present domestic a few can be extracted from plasma blood products manufacturing enterprises, one of the six components are of clotting co-stimulating products is one of the most complete production enterprises, currently has 11 species of blood products product advantages and competitiveness.
M&a integration drives. In 2014, the company completed its acquisition of zhengzhou lez and tonglu biology, and a wholly owned subsidiary in 2016 completed a 90 per cent stake in zhejiang haikang. Zhengzhou laishi has good experience in the sizing, sizing and refining management of individual pulp stations. It has advantages in the management of pulp station, product rate, and special products, etc. Zhejiang haikang is the only blood product enterprise in zhejiang province, with certain geographical advantages. After merger and acquisition integration, Shanghai laishi has been promoted in the management of pulp station, production management, procurement and sales channel management.
Waran organism: net profit was 780 million yuan, up 332.45% year on year
In 2016, the waran organism realized revenue of 19.35 billion yuan, up 31.45% year on year. The net profit attributable to listed company shareholders was 780 million yuan, up 32.3 percent year on year.
Chongqing is the main growth area. Blood products made by hualan bio-engineering 2016 revenue of 1.814 billion yuan, the high-speed growth of 34.03%, of which the static c growth was 73.28%, the industry as a whole supply rapidly increasing and circulation channels change, albumin company growth is slowing to 6.53%, other blood product growth of 37.56%. Chongqing's net profit for 2016 rose 51.43 per cent year on year to the top of the company's performance. In 2016, chongqing's revenue was 730 million yuan, up 541 percent from a year earlier, and net profit was 285 million yuan, a year-on-year increase of 51.43 percent.
The vaccine business has great potential for development. In 2016, the Chinese bio-vaccine business was operating at $108 million, a loss of about $45 million. At present, there are marketed by beads made by hualan bio-engineering, sheet resistance, rituxan and so on four big clinical trials have obtained approval varieties, panitan single resistance, resistance, single, single horse are before conducting clinical research.
Biological shares: net profit of 645 million yuan, up 34.36 percent year on year
In 2016, the revenue of bio-shares was 15.17 billion yuan, up 21.7% year on year. Net profit for listed company shareholders was 64.5 billion yuan, up 34.36 percent year on year.
Biopharmaceutical products are highly gross. In the sector, its bio-pharmaceutical products make 14.48 billion yuan in revenue in 2016, with a gross margin of 78.29%. Other businesses earned 0.38 billion yuan in revenue in 2016. Its main products, the foot-and-mouth disease vaccine, the disease vaccine, the poultry seedling, etc., are excellent.
The attached:
Thirty-seven a-share biopharmaceutical companies in 2016 and net profit
Note: listed companies are classified according to the general letter; The data is based on the eastern wealth network, which is ranked according to the net profit margin.
Image author: how to think
Source: the annual report of the listed companies |
